( Pasteur MSD is the onlycompany in Eur...)Gardasil Demonstrates Up to 100% Efficacy,Health

Pasteur MSD is the only company in Europe dedicated exclusively to vaccines. Sanofi Pasteur MSD is able to draw on the research expertise of sanofi pasteur and Merck & Co., Inc., together with their teams throughout the world, to focus on the development of new vaccines for Europe, which aim to extend protection to other diseases and perfect existing vaccines in order to improve the acceptability, efficacy and tolerability of vaccination.

Contact
Dr. Arne Näveke
Executive Director, Communication Europe
Sanofi Pasteur MSD
Tel +33 4 37 28 40 40
Fax +33 4 37 28 44 04

Clinical study details
a) 551 16-23 year-old women were enrolled and vaccinated in a randomised, placebo-controlled trial. Subjects received vaccine or placebo at Day 1, Months 2, and 6. At regular intervals through 3 years, subjects underwent serum anti-HPV testing. A subset (241 subjects) underwent 2 additional years of follow up. Subjects who originally received vaccine were given another dose at Month 60, while placebo subjects initiated a 3-dose vaccine regimen. Anti-HPV responses were measured 1 and 4 weeks post-dose 4 (subjects who originally received vaccine) or post-dose 1 (subjects who originally received placebo).
b) FUTURE I and II are phase III, prospective, double-blind, placebo-controlled randomised studies conducted in 16 countries. The women who participated in the trials were aged 16 to 26 and received three doses of either Gardasil® or placebo at day 1, month 2, and month 6. The primary analyses of these trials evaluated the efficacy of Gardasil® compared to placebo in women who were negative to the relevant Human Papillomavirus types (6, 11, 16 and/or 18) when they started the study, remained free of infection with the relevant Human Papillomavirus types through month 7, received all three doses of Gardasil® within one year and had no protocol violations.
FUTURE I evaluated th
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer